Literature DB >> 9788702

Molecular concepts of IgE-initiated inflammation in atopic and nonatopic asthma.

G Menz1, S Ying, S R Durham, C J Corrigan, D S Robinson, Q Hamid, R Pfister, M Humbert, A B Kay.   

Abstract

Atopic and nonatopic (intrinsic) asthmatics were characterized by a broadly conserved bronchial mucosal proeosinophilic cytokine network in which IL-5 appears to play a key role. Inappropriate IgE-mediated mechanisms may occur in asthma, irrespective of its atopic status, as suggested by elevated serum IgE concentrations and bronchial mucosal expression of FcepsilonRI, IL-4, IL-13, Iepsilon, and Cepsilon. In general, these observations support the concept that these subtypes of asthma, despite showing distinct clinical and biologic features, share many common immunopathologic mechanisms. The most promising future directions of research regarding intrinsic asthma concern the possible identification of novel allergens or antigens, the detailed description of local bronchial mucosal IgE production, and the understanding of a possible macrophage dysfunction. Furthermore, a role for infectious (viral?) or autoimmune processes has yet to be firmly identified in intrinsic asthma. Animal models may also help us to understand the role of IgE and atopy in asthma. Although these are largely IgE-mediated mechanisms, allergen-induced bronchial hyperresponsiveness and eosinophilic inflammation can also occur in the absence of IgE (null mutation of the Cepsilon locus), as shown in a mouse model of hypersensitivity to Aspergillus fumigatus (57). Thus, despite the absence of atopy, IgE-mediated mechanisms may operate in intrinsic asthma (Fig. 1).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788702     DOI: 10.1111/j.1398-9995.1998.tb04934.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

1.  Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review.

Authors:  Jun Lan; Yi Zhang; Min Song; Shan Cai; Hong Luo; Ruoyun OuYang; Pan Yang; Xiaoliu Shi; Yingjiao Long; Yan Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-04

Review 2.  Is there a role for treatment of asthma with omalizumab?

Authors:  H Milgrom
Journal:  Arch Dis Child       Date:  2003-01       Impact factor: 3.791

3.  Serum IgE reactivity profiling in an asthma affected cohort.

Authors:  Tania Dottorini; Gabriella Sole; Luisa Nunziangeli; Francesca Baldracchini; Nicola Senin; Giorgio Mazzoleni; Carla Proietti; Lenuta Balaci; Andrea Crisanti
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

Review 4.  Omalizumab and IgE in the Control of Severe Allergic Asthma.

Authors:  Yasuhiro Gon; Shuichiro Maruoka; Kenji Mizumura
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

5.  Impact of atopy on asthma and allergic rhinitis in the cohort for reality and evolution of adult asthma in Korea.

Authors:  An-Soo Jang; Sang-Heon Kim; Tae-Bum Kim; Heung-Woo Park; Sae-Hoon Kim; Yoon-Seok Chang; Jae Hyun Lee; You Sook Cho; Jung Won Park; Dong-Ho Nahm; Young-Joo Cho; Sang-Heon Cho; Ho Joo Yoon; Byoung-Whui Choi; Hee-Bom Moon; Choon-Sik Park
Journal:  Allergy Asthma Immunol Res       Date:  2012-12-31       Impact factor: 5.764

6.  Serum free IgE guided dose reduction of omalizumab: a case report.

Authors:  Yasuhiro Gon; Reiko Ito; Shuichiro Maruoka; Kenji Mizumura; Yutaka Kozu; Hisato Hiranuma; Yuko Iida; Sotaro Shikano; Shu Hashimoto
Journal:  Allergy Asthma Clin Immunol       Date:  2017-08-31       Impact factor: 3.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.